Items where authors include "Staffurth, J."

Article

Lane, J.A., Donovan, J.L., Young, G.J. et al. (26 more authors) (2022) Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study). BJU International, 130 (3). pp. 370-380. ISSN 1464-4096

Noble, S.M., Garfield, K., Lane, J.A. et al. (24 more authors) (2020) The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer. British Journal of Cancer, 123 (7). pp. 1063-1070. ISSN 0007-0920

Hamdy, F.C., Donovan, J.L., Lane, J.A. et al. (33 more authors) (2020) Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer : the ProtecT three-arm RCT. Health Technology Assessment, 24 (37). pp. 1-175. ISSN 1366-5278

Neal, D.E., Metcalfe, C., Donovan, J.L. et al. (26 more authors) (2020) Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the ProtecT randomised controlled trial according to treatment received. European Urology, 77 (3). pp. 320-330. ISSN 0302-2838

Farnell, D.J.J., Staffurth, J., Sivell, S. et al. (11 more authors) (2020) The ALERT-B questionnaire: A screening tool for the detection of gastroenterological late effects after radiotherapy for prostate cancer. Clinical and Translational Radiation Oncology, 21. pp. 98-103. ISSN 2405-6308

Johnston, T.J., Shaw, G.L., Lamb, A.D. et al. (29 more authors) (2017) Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial. European Urology, 71 (3). pp. 381-388. ISSN 0302-2838

Hamdy, F.C., Donovan, J.L., Lane, J.A. et al. (25 more authors) (2016) 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. New England Journal of Medicine. ISSN 0028-4793

James, N., Pirrie, S., Pope, A. et al. (17 more authors) (2016) TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer. Health Technology Assessment, 20. 53. ISSN 1366-5278

Andronis, L., Goranitis, I., Pirrie, S. et al. (19 more authors) (2016) Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747). BJU International. ISSN 1464-4096

James, N.D., Pirrie, S.J., Pope, A.M. et al. (19 more authors) (2016) Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both. JAMA Oncology, 2 (4). p. 493. ISSN 2374-2437